For more information about pregnancy and Multiple Sclerosis or the Registry, please call BETAPLUS™ support at 800-788-1467. You may also visit the BETAPLUS™ Support program by clicking here

At Bayer HealthCare Pharmaceuticals Inc., we are committed to providing the multiple sclerosis (MS) community with information to help ensure the safety of patients. Bayer HealthCare Pharmaceuticals Inc. has established a prospective pregnancy registry to study the maternal and infant pregnancy outcome in women who have taken BETASERON^® (interferon beta-1b) at any point before the time of conception and/or during pregnancy.

This Registry has been established to evaluate the safety of BETASERON use during pregnancy. Information from the Registry may assist clinicians and patients in making an informed decision should exposure to BETASERON occur around the time of conception or while pregnant.

If you are a physician treating a patient of childbearing potential who is taking BETASERON and has become pregnant, you are encouraged to enroll the patient into the registry.

If you are a patient who has taken at least one dose of BETASERON around the time of conception or while pregnant, you can give the Registry permission to contact your healthcare provider

To enroll a patient or yourself into the Registry, please call (800) 478-7049.

Indications and Usage

BETASERON^® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

IMPORTANT SAFETY INFORMATION

The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache, and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. BETASERON should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. Cases of anaphylaxis have been reported rarely. See "Warnings," "Precautions," and "Adverse Reactions" sections of full Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.